Haleon Recognized in Fast Company’s 2025 Brands That Matter List
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 1 hour ago0mins
- Brand Impact: Haleon has been recognized in Fast Company’s 2025 Brands That Matter list in the Family of Brands category, highlighting its ability to create cultural moments across multiple brands, thereby reinforcing its leadership position in the global consumer health market.
- Consumer Trust: The company's portfolio includes globally recognized brands like Sensodyne, Centrum, and Advil, which are backed by science and committed to transparent communication and meaningful health initiatives, enhancing consumer trust and brand loyalty.
- Innovation-Driven: Through insights-driven innovation and consumer education, Haleon not only meets consumer needs but also enriches cultural conversations surrounding health and self-care, further boosting its competitive edge in the market.
- Global Mission: Haleon’s brands unite under a shared mission to deliver better everyday health to more people, reflecting its strong commitment to consumer wellbeing and laying a foundation for future growth.
HLN.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on HLN
Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is 13.44 USD with a low forecast of 13.44 USD and a high forecast of 13.44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.590
Low
13.44
Averages
13.44
High
13.44
Current: 9.590
Low
13.44
Averages
13.44
High
13.44
Berenberg
Bethan Davies
Buy
maintain
2025-11-07
Reason
Berenberg
Bethan Davies
Price Target
2025-11-07
maintain
Buy
Reason
Berenberg analyst Bethan Davies raised the firm's price target on Haleon to 517 GBp from 507 GBp and keeps a Buy rating on the shares.
Barclays
Overweight -> Equal Weight
downgrade
2025-09-16
Reason
Barclays
Price Target
2025-09-16
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Haleon to Equal Weight from Overweight with a price target of 380 GBp, down from 430 GBp. The U.S. represents 34% of the company's sales and is seeing slower category growth and destocking, the analyst tells investors in a research note. The firm says Haleon has overweight exposure to declining U.S. drug stores. The company cut its 2025 outlook but there remains short-term risks, contends Barclays. It moves to the sidelines pending a plan from Haleon's new U.S. head.
Goldman Sachs
Olivier Nicolai
Neutral -> Buy
upgrade
£440
2025-09-10
Reason
Goldman Sachs
Olivier Nicolai
Price Target
£440
2025-09-10
upgrade
Neutral -> Buy
Reason
Goldman Sachs analyst Olivier Nicolai upgraded Haleon to Buy from Neutral with a 440 GBp price target. The firm sees the company's fundamentals inflecting in fiscal 2026 due to stronger volume, a U.S. recovery and ongoing high-single-digit Oral Health growth. With Haleon's organic sales growth positioned to accelerate into 2026, the shares are trading at an attractive entry point, the analyst tells investors in a research note.
Berenberg
Bethan Davies
Buy
downgrade
2025-08-12
Reason
Berenberg
Bethan Davies
Price Target
2025-08-12
downgrade
Buy
Reason
Berenberg analyst Bethan Davies lowered the firm's price target on Haleon to 500 GBp from 503 GBp and keeps a Buy rating on the shares.
See All Ratings
About HLN
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?